Research Field: Anti-tumor pharmacology; Focus on metabolism reprogramming and related molecular mechanisms during targeted drug resistance and tumor metastasis in lung cancer, discovery and development of novel inhibitors targeting key enzymes in cancer cell metabolism.
Principle Investigator (PI) of Anti-tumor pharmacology lab
Director of Core Facility, Collaborative Innovation Center for Clinical and Translational Science by Ministry of Education & Shanghai
Professor Ying Shen graduated from Shanghai Institute of Materia Medica, Chinese Academy of Sciences and finished her postdoctoral training at University of California San Diego (UCSD). She was appointed as a staff member at Shanghai Jiao Tong University School of Medicine thereafter and promoted to associate professor in 2013, then professor in 2019. Her research work focuses on metabolism reprogramming and related molecular mechanisms during targeted drug resistance and tumor metastasis in lung cancer, discovery and development of novel inhibitors targeting key enzymes in cancer cell metabolism. Relevant works have been published in high-rank SCI journals such as Cell Metabolism and Science Translational Medicine, and have applied five patents (3 of them have been already granted). The cooperation potent have signed a transformation cooperation agreement.
Scientific Research Projects
National Natural Science Foundation of China, 82073868, 2021.01-2024.12;
National Natural Science Foundation of China, 81773748, 2018.01-2021.12;
National Natural Science Foundation of China, 81473232, 2015.01-2018.12;
Shanghai Science and Technology Commission Project, 20S11900100, 2020.10-2023.09.
Ke Huang#, Qian Liang#, Ye Zhou#, Lu-lu Jiang, Wei-ming Gu, Ming-yu Luo, Ya-bin Tang, Yang Wang, Wei Lu, Min Huang, Sheng-zhe Zhang, Guang-lei Zhuang, Qing Dai, Qian-cheng Shen, Jian Zhang, Hui-min Lei, Liang Zhu, De-yong Ye, Hong-zhuan Chen*, Lu Zhou*, Ying Shen*. A novel allosteric inhibitor of phosphoglycerate mutase 1 suppresses growth and metastasis of non-small cell lung cancer. Cell Metabolism, 2019, 30(6):1107-1119. (IF2019: 21.567)
Zhang KR#, Zhang YF#, Lei HM#, Tang YB#, Ma CS, Lv QM, Wang SY, Lu LM, Shen Y*, Chen HZ*, Zhu L*. Targeting AKR1B1 inhibits glutathione de novo synthesis to overcome acquired resistance to EGFR-targeted therapy in lung cancer. Science Translational Medicine, 2021, 13(614): eabg6428. doi: 10.1126/scitranslmed.abg6428. (IF2020: 17.992)
Jiang-Kai Dong#, Hui-Min Lei#, Qian Liang#, Ya-Bin Tang, Ye Zhou, Yang Wang, Shengzhe Zhang, Wen-Bin Li, Yunguang Tong, Guanglei Zhuang, Liang Zhang, Hong-Zhuan Chen*, Liang Zhu*, Ying Shen*. Overcoming erlotinib resistance in EGFR mutation-positive lung adenocarcinomas through repression of phosphoglycerate dehydrogenase. Theranostics, 2018, 8(7):1808-1823. (IF2018: 8.063)
Hui-Min Lei#, Ke-Ren Zhang#, Cong Hui Wang#, Yang Wang, Guang-Lei Zhuang, Li-Ming Lu, Jian Zhang, Ying Shen*, Hong-Zhuan Chen*, Liang Zhu*. ALDH1A1 confers erlotinib resistance via facilitating the ROS–RCS metabolic pathway in lung adenocarcinomas. Theranostics, 2019, 9 (24): 7122-7139. (IF2019: 8.579)
Qian Liang#, Wei-ming Gu#, Ke Huang#, Ming-yu Luo, Jing-hua Zou, Guang-lei Zhuang, Hui-min Lei, Hong-zhuan Chen, Liang Zhu*, Lu Zhou*, Ying Shen*. HKB99, an allosteric inhibitor of phosphoglycerate mutase 1, suppresses invasive pseudopodia formation and upregulates plasminogen activator inhibitor-2 in erlotinib-resistant non-small cell lung cancer cells. Acta Pharmacologica Sinica, 2021 Jan;42(1):115-119. https://doi.org/10.1038/s41401-020-0399-1. (IF2020: 6.150)
Chun-shuang Ma#, Qian-ming Lv#, Ke-ren Zhang, Ya-bin Tang, Yu-fei Zhang, Ying Shen*, Hui-min Lei*, Liang Zhu*. NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells. Acta Pharmacologica Sinica, 2021, 42(4): 613–623. doi: 10.1038/s41401-020-0443-1. (IF2020: 6.150)
Ying Shen, Qian Liang, Hong-zhuan Chen, Lu Zhou, Liang Zhu, Wei-ming Guo, Ming-yu Luo. Application of PGAM1 allosteric inhibitor HKB99 in the preparation of drugs for the treatment of lung adenocarcinoma. 2021, China, ZL 201910284333.4, granted patent.
Lu Zhou, Ke Huang, De-yong Ye, Ying Shen, Lu-lu Jiang, Peng-hui Wang, Ti-hui Li, Xiao-dan Zhang, Yong Chu, Qian-Liang. 9, 10-anthraquinone compounds or their pharmaceutically acceptable salts and their medicinal uses. 2022, China, ZL 201810273938.9, granted patent.
Liang Zhu, Ke-ren Zhang, Hong-zhuan Chen, Hui-min Lei, Ya-bin Tang, Yu-fei Zhang, Ying Shen, Chun-shuang Ma, Qian-ming Lv. Application of AKR1B inhibitors in the preparation of drugs for lung cancer. 2022, China, ZL 202010498449.0. granted patent.
Liang Zhu, Hui-min Lei, Ya-bin Tang, Hong-zhuan Chen, Ke-ren Zhang, Qian-ming Lv, Ying Shen, Chun-shuang Ma, Yu-fei Zhang. Application of ENPP1 inhibitors in combination with anticancer drugs in preparation of antitumor drugs. 2020, China, CN202010857037.1.
Han Xiao, Ying Shen, Xin Song, Method of heterologous production of linear triterpene. 2018, China, 201811597099.2